Hope for FOP: new drug aims to stop abnormal bone growth
NCT ID NCT05039515
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 27 times
Summary
This study tested two doses of an oral drug called fidrisertib (IPN60130) in children and adults with fibrodysplasia ossificans progressiva (FOP), a rare condition where bone forms in muscles and soft tissues, causing stiffness and disability. The goal was to see if the drug could reduce new abnormal bone growth compared to a placebo. The trial was terminated early, but results may still offer insights for future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Aichi Children's Health and Medical Center
Ōbu, Japan
-
Children's Hospital Capital Institute of Pediatrics (CIP)
Beijing, China
-
Groupe Hospitalier Necker Enfants Malades
Paris, 75015, France
-
Hopital Lariboisiere
Paris, France
-
Hospital Center Lisbon North, E.P.E- Hospital Santa Maria
Lisbon, Portugal
-
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
-
Hospital Universitario Ramon y Cajal
Pozuelo de Alarcón, 28224, Spain
-
Hospital Universitario Y Politecnico La Femerge
Valencia, 46026, Spain
-
Instituto Nacional De Rehabilitacion
Mexico City, Mexico
-
Irccs Gaslini Institute
Genoa, 16147, Italy
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Nagoya University Hospital
Nagoya, Japan
-
Norrlands Universitetssjukhus
Umeå, Sweden
-
Peking Union Medical College Hospital
Beijing, China
-
Royal North Shore Hospital - New South Wales
Sydney, Australia
-
Seoul National University Hospital
Seoul, South Korea
-
Shangai Children Medical Center
Shanghai, China
-
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
The Perelman School of Medicine - The University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
The University of Tokyo Hospital
Tokyo, Japan
-
Tongi University - Tongi Hospital
Shanghai, China
-
University Health Network (UHN), Toronto General Hospital (TGH)
Toronto, Canada
-
University Hospitals Leuven
Leuven, Belgium
-
University of Alberta, Alberta Health Services (AHS)
Edmonton, Canada
-
University of California San Francisco (UCSF)
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.